NCT02476175View on ClinicalTrials.gov

Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

June 30, 2016

Conditions
Overactive BladderUrinary Incontinence
Interventions
DRUG

Mirabegron

Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).

All Listed Sponsors
lead

CHU de Quebec-Universite Laval

OTHER

NCT02476175 - Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder | Biotech Hunter | Biotech Hunter